摘要
目的:探讨晚期前列腺癌(Pca)患者药物去势治疗过程中疗效与Gleason评分及血清前列腺特异性抗原(PSA)的相关性。方法:选择33例晚期Pca患者,给予黄体激素释放激素类似物(LHRH—A)+抗雄激素药物进行药物去势治疗,根据Gleason评分分为2~5分组、6~7分组、8~10分组,对3组血清PSA变化进行分析。结呆:Gleason评分6~7分组的病人在治疗后3个月内血清PSA值下降最快,治疗后6个月时Gleason评分2~5分组病人血清PSA值恢复正常,而Gleason评分6~7分组与8~10分组病人血清PSA值则接近正常值范围。不同Gleason评分组间血清PSA水平差异有统计学意义(F=5.396,P〈O.05)。结论:(1)Gleason评分、血清PSA水平与晚期Pca患者行药物去势疗法疗效有密切关系。(2)血清PSA变化是监测Pca复发与评价疗效的可靠瘤标。
Objective. To probe into the correlation of Gleason score and serum PSA level during medical castration in metastatic prostate cancer patients. Methods. We treated metastatic prostate cancer patients with luteinizing hormone-releasing hormone analog, (LHRH-A) and androgen ablation drug (Flutamide), and combined with the change of Gleason score and serum PSA level, We have a statistical analysis elevate the efficacy of treatment. Results. The levels of the serum PSA during the treatment significantly decreased in 3 months among the groups of Gleason score between 6-7. The level of the serum PSA during the treatment returned to normal in 6 months among the groups of Gleason score between 2-5, but the groups of Gleason score between 6-7 and 8-10 were near to normal and the level of serum of PSA among different groups of Gleason score with significantly different (F = 5. 396, P 〈0.05). Statistically signifi- cant differences were found in those. Conclusions: (1) The Gleason score and the level of the serum PSA have a close relation to the efficacy of medical castration in the treatment of metastatic prostate cancer patients. (2)The change of PSA level is a valuable marker for watching the recurrent and effective of tumor.
出处
《新疆医科大学学报》
CAS
2007年第1期46-47,50,共3页
Journal of Xinjiang Medical University